 VANCOUVER, British Columbia, Aug. 25, 2021 GLOBE NEWSWIRE -- BetterLife Pharma Inc. BetterLife or the Company CSE: BETR OTCQB: BETRF FRA: NPAU , an emerging biotechnology company primarily focused on developing compounds to treat neurological conditions, is pleased to announce initiation of in vitro studies of its recombinant human interferon alpha-2b rhIFN2b or AP-003 against the Delta variant of SARS-CoV-2. The studies are being conducted at Dr. Stephen Barrs Laboratory at the state-of-the-art ImPaKT Facility at Western University UWO. AP-003s first proposed target indication is for people at higher risk to develop severe COVID-19 disease. 